
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Dermatologists and other isotretinoin (Accutane) prescribers soon will be mailed a new brochure on how to recognize psychiatric disorders in the pediatric population.